The fact that hypertension exist in combination with these metabolic diseases has led to the findings that PPAR and FXR agonists can improve vascular function and lower blood pressure (Lalloyer and Staels, 2010; Fang, et al., 2021). Here, PPARA is linked to metabolic disease.